


KDM5-IN-1

Cat. No.:	HY-100422		
CAS No.:	1628210-26-3		
Molecular Formula:	C ₁₇ H ₂₀ N ₆ O		
Molecular Weight:	324.38		
Target:	Histone Demethylase		
Pathway:	Epigenetics		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 30 mg/mL (92.48 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent	1 mg	5 mg	10 mg
	Concentration			
	1 mM	3.0828 mL	15.4140 mL	30.8280 mL
	5 mM	0.6166 mL	3.0828 mL	6.1656 mL
	10 mM	0.3083 mL	1.5414 mL	3.0828 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.08 mg/mL (6.41 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 2.08 mg/mL (6.41 mM); Clear solution
- Add each solvent one by one: 5% DMSO >> 40% PEG300 >> 5% Tween-80 >> 50% saline
 Solubility: ≥ 2.5 mg/mL (7.71 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

KDM5-IN-1 is a potent, selective and orally bioavailable KDM5 inhibitor with an IC₅₀ of 15.1 nM.

IC₅₀ & Target

IC₅₀: 15.1 nM (KDM5); EC₅₀: 0.34 μM (PC9 H3K4Me3)^[1]

In Vitro

KDM5-IN-1 is found to potently inhibit KDM5B and KDM5C isoforms (IC₅₀ of 4.7 and 65.5 nM, respectively). It is significantly less potent against other KDM enzymes (1A, 2B, 3B, 4C, 5A, 6A, 7B), inhibiting KDM4C the strongest with an IC₅₀ of 1.9 μM.

KDM5-IN-1 still displays more than 100-fold selectivity for KDM4C vs. KDM5A^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

When dosed orally in mice at 50 mg/kg twice a day, KDM5-IN-1 shows an unbound maximal plasma concentration C_{max} >15-fold over its cell EC_{50} , thereby providing a robust chemical probe for studying KDM5 biological functions in vivo^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Liang J, et al. Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies. *Bioorg Med Chem Lett*. 2016 Aug 15;26(16):4036-41.

Caution: Product has not been fully validated for medical applications. For research use only.